Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.7.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 11,438 $ 10,551
Marketable securities, current 6,163 13,000
Notes receivable 2,000 0
Prepaid expenses and other current assets 352 623
Total current assets 19,953 24,174
Property and equipment, net 0 109
Total assets 19,953 24,283
Current liabilities:    
Accounts payable 328 822
Collaboration payable 0 129
Accrued clinical and development expenses 178 777
Accrued liabilities 1,704 888
Total current liabilities 2,210 2,616
Warrant liability 2,407 1,743
Deferred rent 9 36
Total liabilities 4,626 4,395
Commitments and contingencies (Note 7)
Stockholders’ equity:    
Preferred stock, $0.001 par value, 2,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value, shares authorized: 150,000,000 shares; issued and outstanding: 71,591,518 shares at March 31, 2017 and 71,560,294 shares at December 31, 2016 72 72
Additional paid-in capital 373,864 373,352
Accumulated other comprehensive loss (1) (2)
Accumulated deficit (358,608) (353,534)
Total stockholders’ equity 15,327 19,888
Total liabilities and stockholders’ equity $ 19,953 $ 24,283